3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
2
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Colorectal Neoplasms
38
Pancreatic Neoplasms
16
Colonic Neoplasms
12
Rectal Neoplasms
11
Stomach Neoplasms
9
Neoplasms
9
Neuroblastoma
8
Small Cell Lung Carcinoma
7
Rhabdomyosarcoma
7
Neoplasm Metastasis
7
Glioblastoma
7
Sarcoma, Ewing
6
Gastrointestinal Neoplasms
6
Central Nervous System Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Glioma
5
Sarcoma
4
Brain Neoplasms
4
Medulloblastoma
3
Intestinal Neoplasms
3
Gliosarcoma
3
Gastrointestinal Diseases
3
Esophageal Neoplasms
3
Digestive System Neoplasms
3
Digestive System Diseases
3
Astrocytoma
3
Advanced Solid Tumors
3
Recurrence
2
Rectal Diseases
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Interventions
Temozolomide
3
Filgrastim
2
Drug Therapy
2
talazoparib
1
sargramostim
1
pembrolizumab
1
oblimersen
1
irinotecan sucrosofate
1
etoposide phosphate
1
entrectinib
1
atezolizumab
1
X-Rays
1
Vincristine
1
Specimen Handling
1
Radiotherapy
1
Radiosurgery
1
Proteasome Inhibitors
1
Platinum
1
Phantoms, Imaging
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
Monatide (IMS 3015)
1
Microarray Analysis
1
Lenalidomide
1
Isotretinoin
1
Irinotecan
1
Immunomodulating Agents
1
Immunohistochemistry
1
Ifosfamide
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Wilms Tumor
×
Irinotecan
×
Clear all
NCT05384821
2026-03-18
MetroWilms
Centre Oscar Lambret
Phase 1/2
Recruiting
28 enrolled